Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called.

1. Planned registration period 1.5 years 2. Planned surveillance period 3 years from the start of this survey

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Nonhodgkin Agranulocytosis Bone Marrow Diseases Bone Marrow Failure Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukocyte Disorders Leukopenia Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neutropenia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma

Exclusion criteria

Treatment and study plan

Primary outcomes

Adverse Events (AEs)

Time frame: Up to approximately 3 years

Number of participants with adverse events

Sponsors and collaborators

Lead sponsor

Celgene

Industry

Registry information

Official study title

Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma)

Important dates

Study start: 2020
Primary completion: 2025
Study completion: 2025
First posted: Nov 5, 2020
Registry last updated: Jul 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting